Search

Displaying results 1181 - 1190 of 10000 in total
  1. Drug

    Tocopherol

    go.drugbank.com/drugs/DB11251
    ApprovedInvestigational

    Tocopherol exists in four different forms designated as α, β, δ, and γ. They present strong antioxidant activities, and it is determined as the major form of vitamin E. … Tocopherol, as a group, is composed of soluble phenolic compounds that consist of a chromanol ring and a 16-carbon phytyl chain.

    Mixtures: Anti-Stretch Mark, Udamin SpCategories: Vitamin E, tocopherol (vit E)
  2. Drug

    Nusinersen

    go.drugbank.com/drugs/DB13161
    ApprovedInvestigational

    FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.

    Categories: Survival Motor Neuron-2-directed RNA InteractionProducts: SPİNRAZA 12 MG/5 ML INTRATEKAL ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, SPINRAZA ®12 MG SOLUCION INYECTABLE
  3. Drug

    Voretigene neparvovec

    go.drugbank.com/drugs/DB13932
    ApprovedInvestigational

    It is not pathogenic and it causes a very mild immune response. … Voretigene Neparvovec-rzyl (VN-rzyl) is an adeno-associated virus vector-based gene therapy.[L1094] An adeno-associated virus is a small virus that infects humans and other primates.

  4. Drug

    Aspartyl-alanyl-diketopiperazine

    go.drugbank.com/drugs/DB14940
    Investigational

    Aspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).

  5. Drug

    Remtolumab

    go.drugbank.com/drugs/DB15128
    Investigational

    Remtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12

  6. Drug

    MVR-C5252

    go.drugbank.com/drugs/DB30379
    Investigational

    MVR-C5252 is a biologic drug. MVR-C5252 is under investigation in clinical trial NCT06126744 (Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252).

  7. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  8. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    [L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: BRAFTOVI® 75 MG CÁPSULAS
  9. Drug

    OT-730

    go.drugbank.com/drugs/DB16112
    Investigational

    OT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma).

  10. Pathway

    Intracellular Signalling Through Adenosine Receptor A2b and Adenosine

    smpdb.ca/view/SMP0000321
    Signaling

    The adenosine receptor A2b activates G(s) proteins which lead to the activation of adenylyl cyclase which produces the secondary messenger cAMP. cAMP activates PKA (protein kinase A) which phosphorylates

    Drugs: ATP · Adenosine · Magnesium cation · Zinc · Cyclic adenosine monophosphate · Pyrophosphoric acid
    Enzymes: Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12, Guanine nucleotide-binding protein G(s) subunit alpha isoforms short